Table 5.
Immunologic response of patients receiving fowlpox immunization
|
In vitro sensitization assay (day 12) using the following peptide |
||||||
|---|---|---|---|---|---|---|
| Fowlpox administrationa | 209–217 | 209–217 (210M) | 280–288 | 280–288 (288V) | 154–162 | FluM1: 58–66 |
| Native rF-gp100 i.v. | 1/7b | 1/7 | 1/7 | 1/7 | 1/7 | 7/7 |
| Modified rF-Mgp100 i.v. | 4/14 | 8/14 | 7/14 | 10/14 | 1/14 | 13/14 |
| rF-gp100:ER209-2M | ||||||
| i.v. | 5/8 | 5/8 | N.A.c | N.A. | N.A. | 7/8 |
| im. | 7/8 | 6/8 | N.A. | N.A. | N.A. | 7/8 |
a
5–6 × 109 plaque-forming units every 2–4 weeks; lymphocytes were tested 2–3 weeks after two immunizations.
b
All assays tested against T2 cells pulsed with 1 µm native (unmodified) peptide; a positive response is defined as secretion of IFN-γ by PBMCs stimulated by the specific peptide at least twice that stimulated by a control peptide. Values represent number of patients positive/total tested.
c
N.A., not applicable.